The Rheumatology Network gout clinical focus page provides information on the latest gout news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for gout drugs.
June 29, 2022
The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases.
June 28, 2022
Take a few minutes to discover Rheumatology Network's most-viewed EULAR 2022 coverage.
June 25, 2022
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.
June 22, 2022
Investigators identified novel biomarkers of incident gout and replicated novel metabolomic biomarkers of gout, including plasma levels of glycoprotein acetyls.
June 14, 2022
Differences among baseline clinical and laboratory characteristics between cases and controls were observed in those with a presence of subcutaneous tophi and higher serum urate levels.
June 02, 2022
John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.
May 14, 2022
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2022.
May 11, 2022
While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.
April 13, 2022
“Understanding the drivers of this increased risk in women with gout warrants further investigation in larger datasets," investigators stated.
April 05, 2022
Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.